Skip to main content

Advertisement

SpringerLink
Log in

How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective

  • Commentary
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

In silico HLA-binding algorithms and in vitro T cell-based assays as predictive tools for human immunogenicity risk have made inroads in the biotherapeutic drug discovery and development process. Currently, these tools are being used only for candidate selection or characterization and not for making a go/no-go decision for further development. A clear limitation for a broader implementation is the lack of correlation between the predicted T cell epitope content/immune reactivity potential of a biotherapeutic and the subsequent ADA-related clinical immunogenicity outcome. The current state of technologies and their pros and cons were discussed as a part of the 2016 AAPS National Biotechnology Conference in a themed session. A review of the advances in the area and the session talks along with the ensuing discussions are summarized in this commentary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534–55.

    Article  CAS  PubMed  Google Scholar 

  3. Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016;8(3):536–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Xue L, Hickling T, Song R, Nowak J, Rup B. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody. Clin Exp Immunol. 2016;183(1):102–13.

    Article  CAS  PubMed  Google Scholar 

  5. Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjaer SB, et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci Transl Med. 2017;9(372):eaag1286.

  6. Mazor R, Onda M, Pastan I. Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev. 2016;270(1):152–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, et al. Recombinant immunotoxin with T cell epitope mutations that greatly reduce immunogenicity for treatment of mesothelin-expressing tumors. Mol Cancer Ther. 2015;14(12):2789–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jawa V, Joubert MK, Zhang Q, Deshpande M, Hapuarachchi S, Hall MP, et al. Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics. AAPS J. 2016;18(6):1439–52.

    Article  CAS  PubMed  Google Scholar 

  9. Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS One. 2016;11(8):e0159328.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, et al. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105(2):417–30.

    Article  CAS  PubMed  Google Scholar 

  11. Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, et al. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 2016;105(5):1567–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009;131(2):189–201.

    Article  PubMed  Google Scholar 

  13. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013;9(7):1577–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008;112(8):3303–11.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kim Y, Sette A, Peters B. Applications for T cell epitope queries and tools in the immune epitope database and analysis resource. J Immunol Methods. 2011;374(1–2):62–9.

    Article  CAS  PubMed  Google Scholar 

  16. Haile LA, Puig M, Kelley-Baker L, Verthelyi D. Detection of innate immune response modulating impurities in therapeutic proteins. PLoS One. 2015;10(4):e0125078.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Rosenberg AS, Verthelyi D, Cherney BW. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J Pharm Sci. 2012;101(10):3560–7.

    Article  CAS  PubMed  Google Scholar 

  18. Verthelyi D, Wang V. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS One. 2010;5(12):e15252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself. 2010;1(4):314–22.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256–65.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T cell immune responses. J Biol Chem. 2012;287(30):25266–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Davies V, Vaughan K, Damle R, Peters B, Sette A. Classification of the universe of immune epitope literature: representation and knowledge gaps. PLoS One. 2009;4(9):e6948.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Paul S, Lindestam Arlehamn CS, Scriba TJ, Dillon MB, Oseroff C, Hinz D, et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods. 2015;422:28–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs. 2010;24(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  25. Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, Gottlieb S, et al. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T cell responses in vitro. PLoS One. 2014;9(1):e86322.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, et al. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol. 2007;124(1):26–32.

    Article  CAS  PubMed  Google Scholar 

  27. Dhir V, Fort M, Mahmood A, Higbee R, Warren W, Narayanan P, et al. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J Immunotoxicol. 2012;9(1):34–42.

    Article  CAS  PubMed  Google Scholar 

  28. Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, et al. Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors. Front Immunol. 2017;8:500.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Schultz HS, Reedtz-Runge SL, Backstrom BT, Lamberth K, Pedersen CR, Kvarnhammar AM, et al. Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell: PBMC assay. PLoS One. 2017;12(5):e0178544.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ing M, Gupta N, Teyssandier M, Maillere B, Pallardy M, Delignat S, et al. Immunogenicity of long-lasting recombinant factor VIII products. Cell Immunol. 2016;301:40–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb, Waltham, Massachusetts, USA

    Jochem Gokemeijer

  2. Biologics and Vaccine Formulations, Merck Sharp & Dohme Corp, 2000 Galloping Hill Road, K-15 H406, Kenilworth, New Jersey, 07033, USA

    Vibha Jawa

  3. Biomarker and Clinical Bioanalysis, Sanofi, 1 The Mountain Road, Framingham, Massachusetts, 01701, USA

    Shibani Mitra-Kaushik

Authors
  1. Jochem Gokemeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vibha Jawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shibani Mitra-Kaushik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shibani Mitra-Kaushik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gokemeijer, J., Jawa, V. & Mitra-Kaushik, S. How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective. AAPS J 19, 1587–1592 (2017). https://doi.org/10.1208/s12248-017-0143-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-017-0143-z

KEY WORDS

Search

Navigation